ZA982371B - Humanized anti-human fas antibody - Google Patents
Humanized anti-human fas antibodyInfo
- Publication number
- ZA982371B ZA982371B ZA982371A ZA982371A ZA982371B ZA 982371 B ZA982371 B ZA 982371B ZA 982371 A ZA982371 A ZA 982371A ZA 982371 A ZA982371 A ZA 982371A ZA 982371 B ZA982371 B ZA 982371B
- Authority
- ZA
- South Africa
- Prior art keywords
- humanized anti
- fas antibody
- human fas
- human
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6793897 | 1997-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA982371B true ZA982371B (en) | 1998-09-28 |
Family
ID=13359383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA982371A ZA982371B (en) | 1997-03-21 | 1998-03-19 | Humanized anti-human fas antibody |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0866131A3 (cs) |
| KR (1) | KR19980080514A (cs) |
| AR (1) | AR012148A1 (cs) |
| AU (1) | AU736287B2 (cs) |
| BR (1) | BR9800937A (cs) |
| CA (1) | CA2232828A1 (cs) |
| CZ (1) | CZ85898A3 (cs) |
| HU (1) | HUP9800613A3 (cs) |
| ID (1) | ID20065A (cs) |
| IL (1) | IL123756A0 (cs) |
| NO (1) | NO981272L (cs) |
| NZ (1) | NZ330004A (cs) |
| PL (1) | PL325457A1 (cs) |
| TR (1) | TR199800517A3 (cs) |
| ZA (1) | ZA982371B (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| EP1087993B1 (en) | 1998-06-18 | 2008-04-02 | Imed Ab | Fas peptides and antibodies for modulating apoptosis |
| AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| EP1143994B1 (en) * | 1999-01-11 | 2003-07-02 | Leadd B.V. | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of (auto)immune diseases |
| AU2004233486B2 (en) * | 1999-01-11 | 2007-09-13 | Leadd B.V. | Use of apoptosis inducing agents in the treatment of (auto)immune diseases |
| MXPA01012206A (es) | 1999-05-24 | 2002-06-21 | Sankyo Co | Composiciones farmaceuticas que contienen anticuerpo anti-fas. |
| WO2003072736A2 (en) * | 2002-02-21 | 2003-09-04 | Duke University | Reagents and treatment methods for autoimmune diseases |
| US20060083738A1 (en) * | 2002-05-17 | 2006-04-20 | Fusion Antibodies Limited | Treatment of cancer by the use of anti fas antibody |
| GB0306618D0 (en) * | 2003-03-22 | 2003-04-30 | Univ Newcastle | Antibody |
| EP1999148B8 (en) | 2006-03-06 | 2014-03-05 | Medlmmune, LLC | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US8030026B2 (en) * | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
| CA3004830A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1995010540A1 (en) * | 1993-10-14 | 1995-04-20 | Immunex Corporation | Fas antagonists and uses thereof |
| CA2158822C (en) * | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Therapeutic agent for rheumatic disease |
| AU724579B2 (en) * | 1996-04-01 | 2000-09-28 | Sankyo Company Limited | Anti-Fas recombinant antibodies and DNA therefor |
-
1998
- 1998-03-19 IL IL12375698A patent/IL123756A0/xx unknown
- 1998-03-19 ZA ZA982371A patent/ZA982371B/xx unknown
- 1998-03-19 AU AU59375/98A patent/AU736287B2/en not_active Ceased
- 1998-03-20 NO NO981272A patent/NO981272L/no unknown
- 1998-03-20 PL PL98325457A patent/PL325457A1/xx unknown
- 1998-03-20 CA CA002232828A patent/CA2232828A1/en not_active Abandoned
- 1998-03-20 EP EP98302113A patent/EP0866131A3/en not_active Withdrawn
- 1998-03-20 CZ CZ98858A patent/CZ85898A3/cs unknown
- 1998-03-20 KR KR1019980009795A patent/KR19980080514A/ko not_active Withdrawn
- 1998-03-20 ID IDP980403A patent/ID20065A/id unknown
- 1998-03-20 HU HU9800613A patent/HUP9800613A3/hu unknown
- 1998-03-20 TR TR1998/00517A patent/TR199800517A3/tr unknown
- 1998-03-20 NZ NZ330004A patent/NZ330004A/xx unknown
- 1998-03-23 AR ARP980101321A patent/AR012148A1/es unknown
- 1998-03-23 BR BR9800937-0A patent/BR9800937A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO981272L (no) | 1998-09-22 |
| EP0866131A2 (en) | 1998-09-23 |
| HUP9800613A2 (hu) | 1999-02-01 |
| KR19980080514A (ko) | 1998-11-25 |
| NZ330004A (en) | 1998-10-28 |
| IL123756A0 (en) | 1998-10-30 |
| CA2232828A1 (en) | 1998-09-21 |
| CZ85898A3 (cs) | 1998-10-14 |
| HUP9800613A3 (en) | 2001-04-28 |
| AU736287B2 (en) | 2001-07-26 |
| TR199800517A2 (xx) | 1998-10-21 |
| BR9800937A (pt) | 2000-01-11 |
| EP0866131A3 (en) | 1999-12-15 |
| TR199800517A3 (tr) | 1998-10-21 |
| AR012148A1 (es) | 2000-09-27 |
| HU9800613D0 (en) | 1998-05-28 |
| NO981272D0 (no) | 1998-03-20 |
| ID20065A (id) | 1998-09-24 |
| PL325457A1 (en) | 1998-09-28 |
| AU5937598A (en) | 1998-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9503638D0 (en) | Anti-alpha-v-integrin monoclonal antibody | |
| IL128406A0 (en) | Monoclonal antibodies | |
| EP1073464A4 (en) | MONOCLONAL ANTIBODIES WITH REDUCED IMMUNIZABILITY | |
| AU1462300A (en) | Human pan-hcv human monoclonal antibodies | |
| DK1516629T3 (da) | Humaniseret anti-CD-11a antibodies | |
| ZA949341B (en) | Humanized antibodies and uses thereof | |
| HUP0104604A3 (en) | Human monoclonal antibodies to ctla-4 | |
| AU4618193A (en) | Humanized antibodies | |
| AU6702998A (en) | Anti-alphabeta3 humanized monoclonal antibodies | |
| ZA982371B (en) | Humanized anti-human fas antibody | |
| EP0578515A3 (en) | Humanized monoclonal antibodies. | |
| GB9608626D0 (en) | Hepatitis b monoclonal antibodies | |
| AU7072998A (en) | Immunoassays using anti-allotypic monoclonal antibodies | |
| GB9718911D0 (en) | Monoclonal antibodies | |
| AU2596397A (en) | Monoclonal antibody that detects apoptotic antigen | |
| ZA951113B (en) | Tumor assosiated monoclonal antibody 123av16 | |
| EP1106701A4 (en) | MONOCLONAL ANTIBODY DIRECTED AGAINST DYNAMIC TRYPSIN | |
| AP9801381A0 (en) | Anti-human mp52 monoclonal antibody | |
| GB9615027D0 (en) | Monoclonal antibodies | |
| GB9212074D0 (en) | Monoclonal antibody | |
| SG64332A1 (en) | Monoclonal antibody | |
| GB9806698D0 (en) | Chimeric antibodies | |
| IL125204A0 (en) | Anti-bacterial monoclonal antibodies | |
| IL127249A0 (en) | Human monoclonal antibodies to the hepatitis b surface antigen |